New combination actinic keratosis treatment

In the UK, actinic keratosis affects approximately one in four people aged 60 years and over | SCIENCE PHOTO LIBRARY
In the UK, actinic keratosis affects approximately one in four people aged 60 years and over | SCIENCE PHOTO LIBRARY

Actikerall is a combination of salicylic acid (10%) and fluorouracil (0.5%) indicated for the treatment of actinic keratosis. The cutaneous solution is licensed for use on slightly palpable and/or moderately thick hyperkeratotic lesions (grade I/II) in immunocompetent patients. Salicylic acid is a keratolytic agent and fluorouracil inhibits the keratinocyte proliferation seen in actinic keratosis.

The efficacy of the salicylic acid/fluorouracil combination was established in a 12-week Phase III trial that enrolled 470 patients with 4–10 lesions. In the per protocol analysis, 72.0% of patients achieved complete histological clearance of a representative lesion after 12 weeks, compared with 59.1% of those treated with diclofenac gel and 44.8% of those who received placebo.

Actikerall is supplied in a 25ml bottle, sufficient for a course of treatment. It is applied once daily using the integral brush.

View Actikerall drug record

Further Information: Almirall

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in